New Kidney Pathway Found That Controls Water Retention Independently

Scientists at Mayo Clinic have uncovered an additional kidney pathway that manages water retention independently of vasopressin, challenging established biological models. This discovery emerged during investigations into polycystic kidney disease (PKD), an inherited condition that progressively impairs kidney function.

For years, it has been understood that vasopressin is the primary hormone enabling kidneys to conserve water and prevent dehydration. However, the research team led by nephrologist Fouad Chebib, M.D., found a previously unknown mechanism allowing the kidneys to concentrate urine without relying on vasopressin. Their findings were published on June 16, 2026, in the Journal of Clinical Investigation.

Unexpected Findings in PKD Research

The research originated from studies on PKD, which affects millions globally and involves the growth of fluid-filled cysts in the kidneys, often culminating in kidney failure. Approximately 140,000 Americans suffer from the autosomal dominant form of PKD (ADPKD), many of whom eventually require dialysis or transplantation.

While examining cellular models of kidney cyst development, the team tested various compounds anticipated to worsen the disease by enhancing signals linked to cyst growth. One such compound was probenecid, a drug introduced in the 1940s to reduce penicillin excretion in urine. Contrary to expectations, probenecid slowed cyst progression rather than accelerating it.

Urate Signaling and Water Reabsorption

Further analysis revealed that probenecid influences how kidney cells handle urate, a molecule commonly associated with gout. Inside cells, urate functions as a signaling agent that prompts water channels to relocate to the cell surface, enabling water reabsorption and urine concentration independently of vasopressin.

Dr. Chebib explained that this pathway is distinct from traditional physiological models and demonstrates an alternative kidney mechanism for water preservation.

Implications for PKD Treatment

The discovery addresses a significant challenge in PKD therapy. Tolvaptan, the only approved medication for slowing cyst growth, operates by blocking vasopressin but causes patients to produce large urine volumes, often between 6 to 7 liters daily. These side effects can be difficult to tolerate and sometimes lead to discontinuation of treatment.

In preclinical studies and a small clinical trial, adding probenecid reduced urine output by about 30% and decreased nighttime urination frequency without compromising tolvaptan’s effectiveness. Patients reported improved quality of life, with many waking fewer times overnight to urinate.

Future Directions for Targeted Therapies

Despite promising results, probenecid is not considered a long-term solution due to its age, broad biological effects, and limited availability. The research team is focusing on developing therapies specifically targeting the newly identified kidney pathway.

“Probenecid helped us uncover the mechanism,” Dr. Chebib said. “Our goal is to take this insight and develop therapies designed specifically for this pathway.”

Dr. Chebib noted the personal significance of this research, which began after his father’s PKD diagnosis, describing it as a meaningful journey with potential patient benefits.